Physician

Donald Gene Rubenstein, M.D.

According to 2025 Medicare claims, Donald Rubenstein, M.D. (NPI: 1912966276) practices cardiac electrophysiology in the Newark, NJ market, with the plurality of this provider's patient population coming from Essex, NJ. This provider's primary affiliated billing organization is BARNABAS HEALTH MEDICAL GROUP PC (NPI: 1841557246; TIN: 454832340) and primary practice location at 07052-2750. Rubenstein is affiliated with the Optimus Healthcare Partners, LLC (ACO ID: A1059), RWJBH Accountable Care, LLC (ACO ID: A1247), and Vytalize Health 9 ACO LLC (ACO ID: D0313), participating under both the MSSP and REACH models.

Rubenstein's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 2,228 traditional Medicare patients, billed 6,390 HCPCS/CPT codes, and received $224,433 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 4,936 prescription claims across 957 beneficiaries totaling $944,862 in drug costs, led by Eliquis (Apixaban). 2018 DME data shows 45 claims. Open Payments data shows 70 records totaling $3,100. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have risen steadily, from $534,104 to $944,862. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	2,276	7,258	$305,742
2016	2,356	7,341	$296,833
2017	2,252	6,918	$279,277
2018	2,316	6,966	$258,329
2019	2,017	5,975	$239,202
2020	1,936	5,392	$237,104
2021	1,734	5,280	$281,127
2022	1,671	5,062	$247,307
2023	2,260	6,734	$255,181
2024	2,228	6,390	$224,433

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	578	4,389	$534,104
2016	585	4,299	$620,946
2017	630	3,478	$640,767
2018	604	2,891	$442,980
2019	598	2,677	$517,243
2020	571	2,766	$572,192
2021	620	3,397	$683,098
2022	703	3,651	$652,237
2023	819	4,126	$941,119
2024	957	4,936	$944,862

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	141	$175,412
2017	N/R	148	$14,360
2018	N/R	45	$2,632
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	386	708	$98
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	469	747	$69
93296	Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days	319	385	$17
93000	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report	645	1,056	$11
93010	Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only	935	1,124	$7

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Eliquis	Apixaban	404	22,821	$438,114
Xarelto	Rivaroxaban	116	6,840	$123,897
Entresto	Sacubitril/Valsartan	79	4,605	$98,991
Multaq	Dronedarone Hcl	20	1,680	$41,862
Jardiance	Empagliflozin	17	990	$17,534

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	68	$1,100	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$2,000	Abbott Laboratories
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Donald Gene Rubenstein, M.D.?

Tedicare shows public-source Medicare data for Donald Gene Rubenstein, M.D. (NPI 1912966276), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Donald Gene Rubenstein, M.D. have ACO affiliation data?

Donald Gene Rubenstein, M.D. is shown with ACO affiliation data for Optimus Healthcare Partners, LLC (MSSP, ACO ID A1059), RWJBH Accountable Care, LLC (MSSP, ACO ID A1247), and Vytalize Health 9 ACO LLC (REACH, ACO ID D0313).

What billing organization is linked to Donald Gene Rubenstein, M.D.?

Donald Gene Rubenstein, M.D. is linked to BARNABAS HEALTH MEDICAL GROUP PC (billing NPI 1841557246) in the available physician profile data.

Does Donald Gene Rubenstein, M.D. have Open Payments data?

Donald Gene Rubenstein, M.D. has 70 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.